A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity

Blood

Volumn 83, Issue 7, 1994, Pages 1760-1768

  Caron, Philip C ^a   Jurcic, Joseph G ^a   Scott, Andrew M ^a   Finn, Ronald D ^a   Divgi, Chaitanya R ^a   Graham, Martin C ^a   Jureidini, Imad M ^a   Sgouros, George ^a   Tyson, Deci ^a   Old, Lloyd J ^a   Larson, Steven M ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M 195;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; TARGET CELL DESTRUCTION;

EID: 0028231359     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v83.7.1760.1760     Document Type: Article

References (29)

1. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8:521, 1984
2. Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW: The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 68:1030, 1986
3. Andrews RG, Singer JW, Bernstein ID: Monoclonal antibody 12-8 recognizes a 115-Kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 67:842, 1986
4. Peiper SC, Ashmun RA, Look AT: Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differential antigen. Blood 72:314, 1988
5. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ: Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 3:339, 1989
6. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD: Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia. Leukemia 3:440, 1989
7. Scheinberg DA, Lovett D, Divgi C, Graham M, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee T, Larson SM, Oettgen H, Old LJ: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478, 1991
8. Sgouros G, Graham M, Divgi CR, Larson SM, Scheinberg DA: Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nuc Med 34:422, 1993
9. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee T, Andreeff M, Old LJ, Larson SM, Scheinberg DA: Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294, 1993
10. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C: Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 148:1149, 1991
11. Caron PC, Co MS, Bull MK, Avdalovic NM, Scheinberg DA: Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52:6761, 1992
12. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA: Determination of immunoreactive fraction of radiolabeled monoclonal anti-body by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77, 1984
13. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Physics 3:253, 1976
14. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220, 1989
15. Co MS, Deschamps M, Whitley RJ, Queen C: Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA 88:2869, 1991
16. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H: Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748, 1992
17. Clendeninn NJ, Nethersell ABW, Scott JE, Collier MA: Phase I/II trials of CAMPATH™-1H, a humanized anti-lymphocyte monoclonal antibody (MoAb), in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 12:158a, 1993 (abstr)
18. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein ID: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54:829, 1992
19. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
20. Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H: Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAM-PATH-1H. Lancet 2:1394, 1988
21. Anasetti C, Hansen JA, Waldmann T, Binger M-H, Mould D, Satoh H, Appelbaum FR, Deeg HJ, Doney K, Martin PJ, Nash R, Sullivan KM, Witherspoon RP, Storb R: Treatment of acute graft-versus-host disease with a humanized monoclonal antibody specific for the IL-2 receptor. Blood 80:373a, 1992 (abstr, suppl 1)
22. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C: Anti-Tac-H, a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50:1495, 1990
23. Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakim J, Benjamin J, Clark WR, Waldmann TA: Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88:2663, 1991
24. Singer II, Kawka DW, DeMartino JA, Daugherty BL, Elliston KO, Alves K, Bush BL, Cameron PM, Cuca GC, Davies P, Forrest MJ, Kazazis DM, Law M-F, Lenny AB, MacIntyre DE, Meurer R, Padlan EA, Pandya S, Schmidt JA, Seamans TC, Scott S, Silberklang M, Williamson AR, Mark GE: Optimal humanization of 1B4, and anti-CD 18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. J Immunol 150:2844, 1993
25. Kotts CE, Hutchins BM, Leddy CA, Su FM, Dodd T, Maneval D, Osaka G, Shalaby R, Fritzberg A, Schroff R: Internalization of humanized monoclonal antibody against p185-HER 2 correlates with HER 2 overexpression. Proc Am Assoc Cancer Res 34:476, 1993
26. Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J: Anti-MY9-blocked-ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 77:2404, 1991
27. Lemoli RM, Gasparetto C, Scheinberg DA, Moore MAS, Clarkson BD, Gulati SC: Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood 77:1829, 1991
28. Stiff PJ, Schulz WC, Bishop M, Marks L: Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia. Blood 77:355, 1991
29. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, Ritz J: Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 79:2229, 1992